bioRxivCell BiologyPreprint
CRISPR/Cas9-mediated deletion of Shp1 and Shp2 reveals distinct roles in human megakaryopoiesis and proplatelet formation
Eugénie SchaefferiD, Elsa BarréiD, Desline HennequiniD, Cécile Loubière, Léa Mallo, Catherine StrasseliD, Christian Andrea Di BuduoiD, Alessandra BalduiniiD, Yotis A. SenisiD, Alexandra MazharianiD
Abstract
The non-receptor protein-tyrosine phosphatases Shp1 (PTPN6) and Shp2 (PTPN11) play critical roles in hematopoietic signaling networks, yet their specific functions in human megakaryopoiesis and thrombopoiesis remain incompletely understood. While Shp2 is recognized in murine models as a positive regulator of thrombopoietin (Tpo)-mediated signaling through the Ras/MAPK and PI3K/AKT pathways, Shp1 has been implicated in RhoA-dependent cytoskeletal remodeling. However, the extent to which these roles translate to human megakaryocyte (MK) development and platelet production is not known. In this study, we systematically investigated the contributions of Shp1 and Shp2 to human MK development and function using CRISPR/Cas9-mediated gene deletion of PTPN6 and PTPN11 in CD34+ hematopoietic stem and progenitor cells (HSPCs), combined with pharmacological inhibition of Shp2 using the structurally-distinct allosteric inhibitors SHP099 and RMC-4550. Efficient gene editing of PTPN6 and PTPN11 resulted in efficient ablation of Shp1 and Shp2 in CD34+ HSPC-derived MKs. Genetic deletion or pharmacological inhibition of Shp2 markedly impaired MK proliferation, polyploidization, maturation, and proplatelet formation, whereas loss of Shp1 expression did not. Further, Shp2 inhibition significantly reduced platelet production in a 3-dimensional human bone marrow tissue model. Deletion and inhibition of Shp2 abrogated Tpo-induced ERK1/2 and AKT phosphorylation, confirming its essential role in Mpl receptor signaling. These findings demonstrate the distinct functional roles of Shp1 and Shp2 in MKs and establish Shp2 as a critical positive regulator of Mpl- mediated megakaryopoiesis and thrombopoiesis. Key PointsO_LIEfficient deletion of Shp1 and Shp2 in human CD34 progenitor cell-derived MKs using CRISPR/Cas9. C_LIO_LILoss of Shp2 expression impairs thrombopoietin-induced human MK maturation, proplatelet formation and Mpl signaling. C_LI
- organism: human
- assay: proteomics
- research focus: cell type annotation
- approach: genetic perturbation / CRISPR
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Synergistic effects of deleting the tyrosine phosphatases Shp1 and Shp2 on megakaryopoiesis and thrombopoiesis in mice
Elsa Barré, Marc‐Damien Lourenco‐Rodrigues, … Alexandra Mazharian·bioRxiv·Oct 24, 2025
- Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation
Ashley P Ng, Maria Kauppi, … Warren S Alexander·bioRxiv·Mar 19, 2014
- Combinatorial effect of miR-486-5p & miR-22-3p mimics thrombopoietin's impact on hematopoietic stem & progenitor cells
C.-Y. Kao, J. Jiang, E. T. PAPOUTSAKIS·bioRxiv·Feb 9, 2020
- ATP11A and ATP11C are plasma membrane phosphatidylserine flippases in in vitro human megakaryocytes.
Ruby M. Baxter, Alexi Crosby, … Matthew Thomas Harper·bioRxiv·Feb 2, 2026
- The intracellular and plasma membrane pools of PI4P control megakaryocyte maturation and proplatelet formation
A. Bura, A. Jurak Begonja·bioRxiv·Jul 28, 2022
- Mathematical modelling of megakaryopoiesis in Mpl-deficient and continuously thrombopoietin-stimulated mice points to an unknown control mechanism
Hans H. Diebner, Andrea Gottschalk, … Ingmar Glauche·bioRxiv·May 29, 2020